Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Aclidinium/Formoterol FDC in COPD
NCT01572792Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of aclidinium, formoterol in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Apr 2012; status: completed.
02
Drugs
aclidiniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01572792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01572792.